



JANSSEN
CAMPUS BELGIUM



Janssen Campus Belgium

Our main concern, in everything we do, is patient care. This has always been our main reason for existing, even after more than 60 years. With our 4,600 employees in Belgium, we aim for breakthrough solutions in the treatment of diseases.



“ We focus on a unique entrepreneurial culture that values and recognizes excellence — and breeds it — both within the organization and in the external community.

Tom Heyman, ceo

WELCOME

We are very pleased to welcome you to Janssen in Belgium, the largest site of the Johnson & Johnson family of companies outside of the United States. We are thrilled to be able to share with you during your visit the excitement of our endless pursuit to meet areas of great unmet medical need.

Our people are tackling the limits of medical science every day, with passion, scientific rigor, and the willingness to take risks and collaborate. The development of medicines that have the potential to alter the course of disease is a complex process that requires a combination of the best minds with the best technologies — and the necessary infrastructure and culture to support both. We are proud to have in Belgium a unique innovation ecosystem covering the complete life cycle of drug development.

From the early start of basic research, over production, commercial and supporting services, market access and the distribution of medicines. As one campus we control the entire pharmaceutical cycle which makes us unique in the pharmaceutical world. We combine our strengths in pharmaceuticals and diagnostics, import ideas, technologies, and talent from our open innovation partners, and collaborate closely to understand market needs and create products that transform lives.

In this quest for innovation, people are our most important resource. We focus on a unique entrepreneurial culture that values and recognizes excellence — and breeds it — both within the organization and in the external community. With more than 4,600 employees and new state-of-the-art facilities, Janssen in Belgium is a key driver of growth for Johnson & Johnson.

Discover how we work towards our goals, utilizing a strong sense of mission, nurturing a creative and productive culture, living the words of our Credo, and providing for both our employees and the greater world, Value through Innovation.

Innovation is our collective aspiration to be the best we can in terms of healthcare solutions, leadership, science and technology, people, teamwork, collaboration, passion and creativity.

Our Research & Development organization continues to push the boundaries of innovation to bring hope for patients and families who are in need. Innovation in the treatment of disease with integrated solutions for individual patients. The face of science and medicine is changing and opening a world of opportunities to advance the field of medicine. Much hope will come from the convergence of science, technology and services. Hope through Innovation.

Our progress in R&D productivity is remarkable. Our two pharmaceutical plants play a central role in the worldwide Supply Chain. Everyday our teams are dedicated to make reliable medicines available, quickly and efficiently, to patients who need them, all over the world. The need for Excellence through Innovation is of paramount importance and embodied in Our Credo by a commitment that “everything we do must be of high quality.”



We look forward to giving you **A WARM WELCOME**



On our Campus **IN BELGIUM** and hope this visit



will inspire you and instill **A GREAT SENSE OF PRIDE**

What matters most to us is a healthy outcome for each patient. We’re committed to providing safe and effective medicines as well as the services and support that contribute to healthy outcomes. This calls for the best science, the most creative minds and an openness to collaborate with researchers, governments and patient organizations at every stage – from early discovery to market access and patient education. With a focus on Outcomes through Innovation and best-in-class commercial capabilities, we expect to continue to make significant contributions to global human health and deliver strong business results for years to come.

We hope to give you some time in the future a warm welcome on our Campus in Belgium.



Tom Heyman
CEO of Janssen Pharmaceutica NV & Global Head of Business Development Janssen Pharmaceutical Companies



We Are Janssen

First of all, we are like everybody else. Ordinary people facing ups and downs in our moods and health, dealing with our little daily worries. Some of us are scientists, some are businessmen, and some are something in between. We have children that we are concerned about, and ageing parents we love dearly. Just like everyone else, we have our hopes and fears and moments of happiness and joy. Like everyone else, we know about pain and distress.

“ Most people may know what we do. Sometimes people ask what we stand for. They want to know who we are.

Secondly, we are a group of people, very diverse in thought, nationality and character, who have come around a dream that was brought to us by Dr. Paul Janssen, the founder of one of our earliest pharmaceutical companies: *we want nothing less than to contribute to the progress of health, and we are willing and able to work hard for it.*

Finally, we are a company. We develop pharmaceutical products to address medical needs that have not yet been met. Once developed, we distribute them around the globe. It is fair to say that our research is essential and expensive.

Therefore economic success is crucial in what we do. In this we are no different from any other company.

However, this success will never let us drift away from the essence: to bring effective and affordable medicines as soon as possible to the patients who are waiting, to bring them help and relief.

We don't just measure our actual gain in dollars or in euros. More important is the number of human lives we save or make better thanks to our medicines. After all these years, that runs into millions too. Is there anything more motivating? We think not.

Now you may think we are dreamers. We will not deny that. Moreover, we are believers. We strongly believe in the impossible. Because we know that it may become possible as you approach it.

Although the process of approaching may demand stubborn perseverance and hard labour, we have proved, on numerous occasions, that it can be done.

This positive and hopeful attitude toward the sometimes very complex problems that we face in our fight against diseases is one of the reasons why, over the decades, we succeeded in developing medicines nobody dreamed of or that were considered to be impossible to develop. *So call us dreamers with a realistic twist.*

To create and distribute these revolutionary medicines, we depend on many people and an enormous amount of knowledge. Even more so now that we find ourselves in uncharted territories again. Satisfactory medicines have been developed for many diseases, and getting new ones out of our labs into the world has become increasingly difficult and costly. We can no longer do it on our own.

To fit into this new environment we have torn down the walls. Today we enjoy the merits of a carefully built global network of partnerships in a variety of different fields. It is a worldwide lab that keeps us aware and enables us to track down all the data that can help us in the challenges we face. These partnerships have become our eyes and ears in our constant search for added value. Through this network we also work closely together with governments, health insurers and health care providers, for we cannot stand the thought of an effective medicine not reaching the patient. *Providing relief will always be our ultimate goal.*

In all this we seek no glory. We seek to contribute in the fight against incurable diseases. We seek solutions to the suffering of our patients. *You may call it idealism, or a perfect business plan. Personally, we feel lucky to call it our job.*

The Janssen History: A Summary

1926 Entrepreneurial genes

Paul Janssen was born 12 September 1926 in Turnhout. His father Constant was a successful general practitioner at the time, but had set his heart on creating his own company. In 1927, he started importing and distributing Richter products, and, in 1934, he founded the N.V. Produkten Richter. The family business concentrated on the distribution of Richter products in Belgium, the Netherlands and the Belgian Congo. Richter is still a successful Hungarian pharmaceutical company, which launched Janssen products onto the markets of several Eastern European countries, until



Janssen established its own network of branches in this region. Constant Janssen introduced products of his own making onto the market for some time after the Second World War, under the name of Eupharma.

1948 A passion for science

After his secondary education at the Sint-Jozef-college in Turnhout, the young Paul Janssen started studies in Namur, at the Faculté Notre Dame de la Paix. The physics, biology and chemistry courses that he attended stimulated his scientific passion even more. Following his conviction that there must be a link between the chemical structure of a substance and its medicinal effect, he took up medicine studies at the University of Leuven in 1945. He moved to the United States in 1948 in order to become acquainted with modern drug research in private laboratories. He graduated as a General Practitioner at the Gentse Rijksuniversiteit (Ghent University) in 1951, and was initially employed as an assistant by several renowned professors in Ghent and Cologne. A great academic career lay ahead of him, ready for the taking, but he wanted to realize his dream and established his own research laboratory in 1953.

1953 First employees

Together with his first employees, Dr. Paul started work on the third floor of his parents' company at the Statiesstraat in Turnhout, in 1953. He was keen to discover the effect that a chemical substance could have on a living organism. His goal was to create chemical compounds with the intention of patenting them as soon as possible, in order to finance his own research with the proceeds. A Dutch physician in a company based in Amsterdam that specialized in this area examined Dr. Paul's first substances with regard to their effectiveness and safety. Together with his first employees, he laid the foundation for his own pharmaceutical company in this way.



1955 Rapid successes

Dr. Paul's first major discovery was ambucetamide, a drug used to relieve menstrual pains, which was launched in 1955. Soon afterwards, several well-known American companies took a number of his first drugs under license, including the painkiller dextromoramide (PALFIUM), which attracted a lot of media attention. The anti-diarrheal drug diphenoxylate (REASEC), very successful in the American market under the brand name LOMOTIL, even traveled to the moon with the Apollo astronauts in 1969. What was Dr. Paul's key to these early successes? His 'positive dissatisfaction', his unwillingness to accept the ultimate limitations of science, his never-changing openness to new developments and the opportunities that reveal themselves.

1957 From Turnhout to Beerse

In 1956, the family company was renamed N.V. Laboratoria Pharmaceutica Dr. C. Janssen. Because the premises were soon bursting at the seams, Dr. Paul moved to Beerse with thirty employees in 1957. The N.V. Research Laboratorium Dr. C. Janssen consisted of a department for synthetic chemistry, a pharmacological laboratory, an analysis laboratory, offices, and areas where test animals were held (mice and rats). Subsequent years saw a rapid and successful expansion at the new campus, a former military training site that was converted into the first industrial site of the town by the municipality of Beerse.



1958 Revolution in psychiatrics

With the synthesis of haloperidol (HALDOL) at the end of the fifties, more specifically in 1958, Paul Janssen launched a true revolution in how mental illness had been treated up to then. Instead of putting patients in straitjackets and administering electroshocks to them, psychotic patients could now be freed from their hallucinations and delusions, and be made ready to take up a virtually normal life in society again. The quest for even better variants resulted in numerous successful Janssen antipsychotics in the years that followed. Thanks to innovative technologies, injectable and long-acting formulations, which are user-friendly and therefore even more effective, were also created.



1960, Powerful painkillers for people & animals

1960 Powerful painkillers for people & animals

What haloperidol brought about in psychiatric care, fentanyl (FENTANYL-JANSSEN) repeated in anesthesia. After 45 years, this product, which was first synthesized in 1960, is still the most widely used analgesic in the world. In recent years, the product has been particularly successful in the form of a patch that is used very effectively in the battle against chronic pain, especially in cancer patients. Sufentanil (SUFENTA) is 1,000 times more powerful than morphine, and can therefore be used for complex surgical procedures, such as heart transplants. Bill Schroeder, the second man to receive an artificial heart during an operation that lasted six hours in 1984, was anesthetized with sufentanil. Another area where powerful Janssen anesthetics are often used is for the transportation of animals between wild parks, such as in Africa.

1961 Janssen part of Johnson & Johnson

In the early sixties, the American company Johnson & Johnson expressed an interest in acquiring N.V. Laboratoria Pharmaceutica Dr. C. Janssen. In Dr Paul's opinion, this was an excellent chance to offer his fast-growing company. In 1961, the two research companies in Turnhout and Beerse, the export company Bepharex and the two Janssen branches in Tilburg and Düsseldorf were fully integrated into Johnson & Johnson. At that time, a successful businessman from Turnhout, Frans Van den Bergh, was Chairman of the Board. He led the negotiations with Johnson & Johnson together with Paul Janssen, and brought them to a successful conclusion. It was also Van den Bergh who suggested the name Janssen Pharmaceutica.



“What’s new?”

Dr. Paul Janssen

(1926-2003)

1970 Pioneering drugs

Several employees of Dr. Paul Janssen had already gained many years of practical experience in the former Belgian colonial territories of the Congo, Rwanda and Burundi. In Beerse, they concentrated on finding promising substances in the field of parasitology, pharmacology, mycology and neurology, for which the expertise they obtained in Africa was an excellent help. The number of employees expanded rapidly: from 377 in 1961 to 807 in 1970 and 1,734 in 1980. Two new departments, Veterinary Medicine (1964) and Plant Protection (1972), were created. It is therefore not surprising that numerous pioneering medicines saw the light of day in the following years, including drugs that are now well-known against moulds, worms, diarrhea, stomach upsets and vomiting, psychosis, and medication for use in anesthetics.

1979 Worldwide expansion

In the seventies and eighties, Janssen Pharmaceutica developed a worldwide network of companies. The Janssen companies in England (1971), Japan (1978), the United States (1979) and China (1985) were established in this way, while research centers also became active in the United States, England, Germany, France and Spain. A special success story was the opening of a fully-owned pharmaceutical pharmacy in Xian (China) at the end of the eighties, with which Janssen made history in this immense country. In 2007, India was added to this list, following the opening of an Analytical & Pharmaceutical Development Center in Mumbai. In this way, Janssen could progress along its own successful course for many years within the multinational Johnson & Johnson.

1995 Development at home

The global expansion of the company also propelled the expansion at home into a higher gear. Janssen opened a first Chemical Production factory (Plant 1) in 1975, at the new company site in Geel. Another three production factories were added later (Plant 2 in 1977, Plant 3 in 1984 and Plant 4 in 1995), as well as a high-tech pilot plant for chemical development (2009). In 1992, Janssen Biotech was founded in Olen for the production of pellets, and a completely new pharmaceutical plant (Plant 1) was constructed on the Beerse campus, next to the existing factory, in 1996. The financial center and the marketing department of Janssen Belgium were accommodated in a modern building on the new company site Beerse 2 (2002). The Dr. Paul Janssen Research Center was opened at the Beerse 1 site in 2004, where also the Drug Safety Evaluation Center followed one year later.

2003 The key to success? Innovation!

Inspired by Dr. Paul, who passed away suddenly on 11 November 2003, devoted Janssen employees continued their search for innovative drugs which resulted in several key products in the last 10 years. Several Janssen medicines, including drugs fighting psychoses (1996), cancer (2006) and psoriasis (2012), won the International Galenus award, which can be compared to a Nobel Prize for scientific innovation. The annual presentation of the Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson as a tribute to our founder Dr. Paul Janssen. This prestigious award also aims to stimulate worldwide innovative research work by highly passionate and creative international scientists.

Janssen Worldwide

You will soon find out that our people are united and energized by just one mission – to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time. That’s what unites us, that’s what drives us and we are looking for you to join our network of talented, mission-driven professionals. With more than 40,000 employees worldwide, operating in more than 150 countries across five continents, Janssen is the fastest growing top 10 pharmaceutical company in Europe, the U.S. and Japan. It was named ‘Most Productive Pharmaceutical Company’ by InnoThink Center for Research in Biomedical Innovation and has a “Partner of Choice” reputation, with more than 150 collaborations with academic institutions, biotechs, public-private partnerships and open campus initiatives.

We have made tremendous progress in the past years, as evident in our pipeline—one of the largest in the industry today. Our progress in R&D productivity is remarkable.

Janssen is part of Johnson & Johnson, a broadly based global healthcare company with expertise in all stages of research and development of large and small molecule therapeutics, vaccines, medical devices, diagnostics and consumer products.

-  **Neuroscience**
-  **Infectious Diseases and Vaccines**
-  **Immunology**
-  **Oncology**
-  **Cardiovascular and Metabolic Diseases**



Quick Facts

- 2013 sales of \$28.1 billion
- Almost one-quarter of Janssen’s sales are re-invested in new product research
- 11 new products launched since 2009
- Fastest-growing Top 10 pharmaceutical company in the U.S., Europe and Japan
- Named ‘Most Productive Pharmaceutical Company’ by InnoThink Center for Research in Biomedical Innovation
- “Partner of Choice” reputation, with more than 150 collaborations with academic institutions, biotechs, public-private partnerships and open campus initiatives

Janssen Campus Belgium

Campus of historical importance

Janssen in Belgium is the largest member of the Johnson & Johnson family of companies outside of the United States. As a place of historical importance for the company, the Campus has been focusing on research & development of innovative medicines for 50 years. Tremendous momentum is being built here following the legacy of Dr. Paul. The company has discovered more than 80 compounds in the areas of schizophrenia, gastroenterology, mycology, parasitology, and pain management. Janssen in Belgium manufactures more than 70 percent of the active ingredients used in pharmaceuticals produced by Johnson & Johnson companies. With our 4,600 employees in Belgium from 30 different nationalities, we aim to give patients worldwide access to breakthrough solutions.

Discovered more than

80
COMPOUNDS


4,600
**EMPLOYEES
IN BELGIUM**

30
**DIFFERENT
NATIONALITIES**



Unique ecosystem covering complete drug development life cycle

The campus has sites in Beerse (Beerse I and II), Geel, Olen, Diegem, La Louvière and Merksem. Together these organizations discover, develop and produce medicines and therapeutic solutions for patients worldwide. From the early start - basic research on new medicines - over production, commercial and supporting services to distribution of medicines. This is how Janssen in Belgium controls the entire pharmaceutical cycle, which makes the company unique in the pharmaceutical world. The integrated environment of our Campus gives our people the chance to experience many different aspects of drug development throughout their career. In recent years, millions have been invested in the Campus to ensure our people have access to strong core facilities and the most modern infrastructure available that fulfills the strictest requirements with regard to quality and safety of our patients and employees.



Quick Facts


- 6 locations
- More than 4,600 employees
- Established in 1953
- Member of Johnson & Johnson since 1961
- More than 80 drugs (five which feature on the WHO's list of essential drugs)
- €1.1 billion investments in R&D in 2013

Unique in the pharmaceutical world

Janssen Campus Belgium has excellent expertise in the field of neurosciences, oncology and infectious diseases. Every day the company and its partners are dedicated to the discovery and development of a new generation of small molecules for the fight against schizophrenia, depressions, pain control, dementia, hepatitis, HIV, different types of cancers,... With state-of-the-art production facilities, Janssen Campus Belgium plays a central role in the worldwide Supply Chain. Everyday our teams are dedicated to make reliable medicines available, quickly and efficiently, to patients who need them.



From Lab To Patient



From Lab To Patient

Disease causes pain and suffering in patients, as well as heartache for their nearest and dearest. Since the early 1990's scientists have discovered and developed more than 300 new treatments for more than 150 disorders. And yet there are still far more diseases than cures today. Science and medicine have undergone groundbreaking changes in recent decades. The opportunities for discovery are greater than ever. And yet the development of life-saving therapies is still an incredibly challenging task. The discovery, the development and production of a new drug takes years: on average as many as fourteen. It is a journey that entails a great many misfortunes and dead-end streets. But with the efforts made by our team, every single day, there is renewed hope for a cure.



Basic Research

Our scientists track down a target that we have to hit in order to treat the disease. Then we go looking for a molecule that will hit that target.



Preclinical Development

The most promising molecules become candidate drugs. We go on to test these in a test-tube, on cells or in live laboratory animals.



Clinical Trials

If the candidate drug is safe enough to be tested on humans, then the clinical trials begin in healthy volunteers (phase I) and patients (phase II and III). We investigate the safety and efficacy of the candidate drug, and how it behaves in the body (absorption, distribution, excretion).



Registration

Only registered drugs can be brought to market. Which is why we have to submit a file containing all the data from the basic, preclinical and clinical research to the government.



Market Access

Once the drug has been registered, production gets into full swing. We provide information to the medical profession, and request a price and reimbursement from the authorities. Once these are obtained, we can distribute the drug to our customers. The safety of the drug is then continually monitored in patients around the world.

The full pharmaceutical cycle on 1 campus

The Janssen Campus in Belgium is a centre of excellence of integrated Research & Development, Supply Chain, Market Access and Supporting Functions.

These organizations work together and cover the complete life cycle of therapeutic solutions for significant unmet medical needs.



Research & Development



Janssen Research & Development in Belgium forms, together with the research centers in other European countries (France, Netherlands, Spain and UK), the United States and Asia Pacific, one global organization. R&D Belgium hosts 1,800 employees from 30 different nationalities and is the largest R&D center of Johnson & Johnson for small molecules. Our focus is to discover, develop and deliver differentiated medicines.

Our researchers are continually searching for innovative molecules and research efforts have already yielded numerous groundbreaking drugs in 3 therapeutic areas: Oncology, Neuroscience, Infectious Diseases; and in Global Public Health. Our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide.



Commercial



Janssen Commercial is committed to leading fundamental change in the way that diseases are managed. In our absolute commitment to patients, we will bring innovative, integrated healthcare solutions that will restore and extend quality of life, while creating economic value for society and our company. Working side-by-side with healthcare stakeholders and building on our peo-

ple's talent we aim to build from our position of strength to demonstrate real value by delivering outcomes. This will enable us to grow and bring transformational medical innovations to even more patients. It will also enable us to become a true partner to healthcare systems and be looked upon with new levels of respect and trust.

Supply Chain



Every day people in the Janssen Supply Chain are dedicated to make reliable medicines available, quickly and efficiently, to patients who need them, all over the world. Two state-of-the-art production facilities are responsible for supplying our medicines to markets around the world. With quality as our primary focus, our mission is to deliver affordable medicines to anyone, anywhere, any day.

Chemical Supply Chain Geel

Janssen Supply Chain Geel is a chemical production site where we produce over 50 different Active Pharmaceutical Ingredients (API) for 4 different therapeutic areas: cardiovascular, infectious diseases, neuroscience and oncology. The Geel production site is the largest chemical API site within Johnson & Johnson and employs 700 passionate professionals. A high-tech production site for the development, launch and growth of new products and for the commercial production of mature products. Since 2011 we launched INCIVO® (hepatitis C), ZYTIGA® (prostate cancer), EDURANT® (HIV), INVEGA® SUSTENNA®/XEPLION® (schizophrenia), SIRTUROT™ (tuberculosis), INVOKANA® (type 2 diabetes), OLYSIOT™ (hepatitis C).

Pharmaceutical Supply Chain Beerse

Janssen Supply Chain Beerse is a pharmaceutical production site where products are formulated, filled and packed to send to the distribution centers. The Active Pharmaceutical Ingredients (API) are produced into liquids and creams, transdermals, parenteral, pellets, aseptic eye drops. Beerse masters complexity in producing more than 50 different pharmaceutical and consumer products in support of 5 different therapeutic areas. The production site has a strong track record in delivering supply chain solutions thanks to a unique combination of proximity to Research & Development, a diverse technology background and a highly skilled and flexible work force.



Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse - Belgium



Our 6 locations

- > Beerse
- > Diegem
- > Geel
- > Olen
- > Merksem
- > La Louvière

Interested in
working in one
of our 6 locations?

Check out our job vacancies at
www.janssenjobs.be



janssenbelgium.be

